431 related articles for article (PubMed ID: 18622026)
1. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression.
Shan W; Palkar PS; Murray IA; McDevitt EI; Kennett MJ; Kang BH; Isom HC; Perdew GH; Gonzalez FJ; Peters JM
Toxicol Sci; 2008 Oct; 105(2):418-28. PubMed ID: 18622026
[TBL] [Abstract][Full Text] [Related]
2. Ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase-2 enhances inhibition of skin tumorigenesis.
Bility MT; Zhu B; Kang BH; Gonzalez FJ; Peters JM
Toxicol Sci; 2010 Jan; 113(1):27-36. PubMed ID: 19748995
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-beta/delta protects against chemically induced liver toxicity in mice.
Shan W; Nicol CJ; Ito S; Bility MT; Kennett MJ; Ward JM; Gonzalez FJ; Peters JM
Hepatology; 2008 Jan; 47(1):225-35. PubMed ID: 18038451
[TBL] [Abstract][Full Text] [Related]
4. Ligand activation of peroxisome proliferator-activated receptor-β/δ suppresses liver tumorigenesis in hepatitis B transgenic mice.
Balandaram G; Kramer LR; Kang BH; Murray IA; Perdew GH; Gonzalez FJ; Peters JM
Toxicology; 2016 Jul; 363-364():1-9. PubMed ID: 27427494
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Cytochrome P450 2B10 (CYP2B10) Expression in Liver by Peroxisome Proliferator-activated Receptor-β/δ Modulation of SP1 Promoter Occupancy.
Koga T; Yao PL; Goudarzi M; Murray IA; Balandaram G; Gonzalez FJ; Perdew GH; Fornace AJ; Peters JM
J Biol Chem; 2016 Nov; 291(48):25255-25263. PubMed ID: 27765815
[TBL] [Abstract][Full Text] [Related]
6. Ligand activation of peroxisome proliferator-activated receptor-beta/delta inhibits cell proliferation in human HaCaT keratinocytes.
Borland MG; Foreman JE; Girroir EE; Zolfaghari R; Sharma AK; Amin S; Gonzalez FJ; Ross AC; Peters JM
Mol Pharmacol; 2008 Nov; 74(5):1429-42. PubMed ID: 18687807
[TBL] [Abstract][Full Text] [Related]
7. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) and inhibition of cyclooxygenase 2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms.
Hollingshead HE; Borland MG; Billin AN; Willson TM; Gonzalez FJ; Peters JM
Carcinogenesis; 2008 Jan; 29(1):169-76. PubMed ID: 17893232
[TBL] [Abstract][Full Text] [Related]
8. Chemoprevention of chemically induced skin tumorigenesis by ligand activation of peroxisome proliferator-activated receptor-beta/delta and inhibition of cyclooxygenase 2.
Zhu B; Bai R; Kennett MJ; Kang BH; Gonzalez FJ; Peters JM
Mol Cancer Ther; 2010 Dec; 9(12):3267-77. PubMed ID: 21159610
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands do not potentiate growth of human cancer cell lines.
Hollingshead HE; Killins RL; Borland MG; Girroir EE; Billin AN; Willson TM; Sharma AK; Amin S; Gonzalez FJ; Peters JM
Carcinogenesis; 2007 Dec; 28(12):2641-9. PubMed ID: 17693664
[TBL] [Abstract][Full Text] [Related]
10. PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism.
Hollingshead HE; Morimura K; Adachi M; Kennett MJ; Billin AN; Willson TM; Gonzalez FJ; Peters JM
Dig Dis Sci; 2007 Nov; 52(11):2912-9. PubMed ID: 17404849
[TBL] [Abstract][Full Text] [Related]
11. Hepatic regulation of VLDL receptor by PPARβ/δ and FGF21 modulates non-alcoholic fatty liver disease.
Zarei M; Barroso E; Palomer X; Dai J; Rada P; Quesada-López T; Escolà-Gil JC; Cedó L; Zali MR; Molaei M; Dabiri R; Vázquez S; Pujol E; Valverde ÁM; Villarroya F; Liu Y; Wahli W; Vázquez-Carrera M
Mol Metab; 2018 Feb; 8():117-131. PubMed ID: 29289645
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor beta/delta activation improves angiotensin II-induced cardiac hypertrophy in vitro.
Sheng L; Ye P; Liu YX; Han CG; Zhang ZY
Clin Exp Hypertens; 2008 Feb; 30(2):109-19. PubMed ID: 18293166
[TBL] [Abstract][Full Text] [Related]
13. Effect of PPAR-β/δ agonist GW0742 treatment in the acute phase response and blood-brain barrier permeability following brain injury.
Chehaibi K; le Maire L; Bradoni S; Escola JC; Blanco-Vaca F; Slimane MN
Transl Res; 2017 Apr; 182():27-48. PubMed ID: 27818230
[TBL] [Abstract][Full Text] [Related]
14. Ligand activation of peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) inhibits cell growth in a mouse mammary gland cancer cell line.
Foreman JE; Sharma AK; Amin S; Gonzalez FJ; Peters JM
Cancer Lett; 2010 Feb; 288(2):219-25. PubMed ID: 19660859
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological PPARβ/δ activation upregulates VLDLR in hepatocytes.
Zarei M; Barroso E; Palomer X; Escolà-Gil JC; Cedó L; Wahli W; Vázquez-Carrera M
Clin Investig Arterioscler; 2019; 31(3):111-118. PubMed ID: 30987865
[TBL] [Abstract][Full Text] [Related]
16. PPARβ/δ activation protects against hepatic ischaemia-reperfusion injury.
Qian B; Wang C; Li X; Ma P; Dong L; Shen B; Wu H; Li N; Kang K; Ma Y
Liver Int; 2023 Dec; 43(12):2808-2823. PubMed ID: 37833850
[TBL] [Abstract][Full Text] [Related]
17. Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) inhibits chemically induced skin tumorigenesis.
Bility MT; Devlin-Durante MK; Blazanin N; Glick AB; Ward JM; Kang BH; Kennett MJ; Gonzalez FJ; Peters JM
Carcinogenesis; 2008 Dec; 29(12):2406-14. PubMed ID: 18799709
[TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-beta/delta (PPARbeta/delta) ligands inhibit growth of UACC903 and MCF7 human cancer cell lines.
Girroir EE; Hollingshead HE; Billin AN; Willson TM; Robertson GP; Sharma AK; Amin S; Gonzalez FJ; Peters JM
Toxicology; 2008 Jan; 243(1-2):236-43. PubMed ID: 18054822
[TBL] [Abstract][Full Text] [Related]
19. The peroxisome proliferator-activated receptor (PPAR) β/δ agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells.
Serrano-Marco L; Barroso E; El Kochairi I; Palomer X; Michalik L; Wahli W; Vázquez-Carrera M
Diabetologia; 2012 Mar; 55(3):743-51. PubMed ID: 22179221
[TBL] [Abstract][Full Text] [Related]
20. PPARβ/δ modulates ethanol-induced hepatic effects by decreasing pyridoxal kinase activity.
Goudarzi M; Koga T; Khozoie C; Mak TD; Kang BH; Fornace AJ; Peters JM
Toxicology; 2013 Sep; 311(3):87-98. PubMed ID: 23851158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
